AstraZeneca Beheer

Beheer criteriumcontroles 3/4

De CEO AstraZeneca is Pascal Soriot, benoemd in Oct2012, heeft een ambtstermijn van 12.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 21.48M, bestaande uit 8.5% salaris en 91.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde ARS 29.80B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.4 jaar en 7 jaar.

Belangrijke informatie

Pascal Soriot

Algemeen directeur

US$21.5m

Totale compensatie

Percentage CEO-salaris	8.5%
Dienstverband CEO	12.1yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	9.4yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Geen updates

Recent updates

Analyse CEO-vergoeding

Hoe is Pascal Soriot's beloning veranderd ten opzichte van AstraZeneca's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$21m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$18m	US$2m	US$3b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	-US$1b
Mar 31 2022	n/a	n/a	-US$1b
Dec 31 2021	US$21m	US$2m	US$112m
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$22m	US$2m	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$20m	US$2m	US$1b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$2m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$3b
Mar 31 2018	n/a	n/a	US$3b
Dec 31 2017	US$14m	US$2m	US$3b

Compensatie versus markt: De totale vergoeding ($USD 21.48M ) Pascal } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de AR markt ($USD 5.72M ).

Compensatie versus inkomsten: De vergoeding van Pascal is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Pascal Soriot (65 yo)

12.1yrs

Tenure

US$21,484,390

Compensatie

Mr. Pascal Soriot, M.B.A., D.V.M., has been the Chief Executive Officer and Executive Director at AstraZeneca PLC since October 1, 2012. He served as Director at Acerta Pharma B.V. He had been Independent...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% ARS 29.8b
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% ARS 11.1b
Pam Cheng	EVP of Global opt. & IT	9.4yrs	geen gegevens	geen gegevens
Andrew Barnett	Head of Investor Relations	no data	geen gegevens	geen gegevens
Jeffrey Pott	CHRO, Chief Compliance Officer	15.8yrs	geen gegevens	geen gegevens
Gonzalo Vina	Head of Global Media Relations	no data	geen gegevens	geen gegevens
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	11.8yrs	geen gegevens	geen gegevens
Susan Galbraith	Executive Vice President of Oncology Research & Development	no data	geen gegevens	geen gegevens
Leon Wang	Executive VP of International & China President	10.8yrs	geen gegevens	geen gegevens
Iskra Reic	Executive Vice-President of Vaccines & Immune Therapies	7.6yrs	geen gegevens	geen gegevens
David Fredrickson	Executive Vice-President of Oncology Business Unit	7.1yrs	geen gegevens	geen gegevens
Ruth March	Senior VP of Precision Medicine - R&D Oncology	5.8yrs	geen gegevens	geen gegevens

9.4yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AZN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Pascal Soriot	CEO & Executive Director	12.1yrs	US$21.48m	0.014% ARS 29.8b
Aradhana Sarin	CFO & Executive Director	3.3yrs	US$5.62m	0.0053% ARS 11.1b
Pam Cheng	EVP of Global opt. & IT	no data	geen gegevens	geen gegevens
Jeffrey Pott	CHRO, Chief Compliance Officer	no data	geen gegevens	geen gegevens
Marcus Wallenberg	Non-Executive Director	25.6yrs	US$159.35k	0.0039% ARS 8.1b
Philip John Broadley	Senior Independent Non-Executive Director	7.6yrs	US$254.96k	0.00052% ARS 1.1b
Michel Demare	Independent Chairman	5.2yrs	US$744.49k	0.00065% ARS 1.4b
Deborah DiSanzo Eldracher	Independent Non-Executive Director	6.9yrs	US$152.98k	0.000060% ARS 125.2m
Sherilyn S. McCoy	Independent Non-Executive Director	7.1yrs	US$223.09k	0.00011% ARS 229.5m
Euan Ashley	Independent Non-Executive Director	4.1yrs	US$151.70k	0.000070% ARS 146.1m
Shu Kam Mok	Independent Non-Executive Director	5.8yrs	US$140.23k	0.00013% ARS 271.3m
Nazneen Rahman	Independent Non-Executive Director	7.4yrs	US$203.97k	0.000070% ARS 146.1m

7.0yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AZN wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

AstraZeneca Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Recent updates

AstraZeneca PLC Announces Positive High-Level Results from the Capitello-281 Phase III Trial

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd